Jim, I appreciate your efforts. Can you give me an idea of your background? You appear to be respected on this board. Thanks!
all with similar results and treating IBS, CIC, and OIC. I really can't imagine results that could not fulfill the objectives of the study. Hope we're right.
Though nothing is certain, the very high number of subjects in previous trials bodes well for a positive outcome. That and the tests are being conducted by the same individual that got Linzness through phase III trials.
Good question. Don't know. Just know that the trials have been designed by the same guy who designed the trials for Ironwood, which should be good news. Considering they work very similarly and Plecanatide has been tested on over 1,500 subjects in it's studies of IBS, CIC, and OIC, that all seem to show similar type results, my jaw would drop and I may throw my computer if results are not good.
With 951 patients in the phase II trial alone for CIC, That provides a pretty good indicator. This is unique as their phase II was impressively and uniquely large. Three test results subjecting over 1,500 subjects to plecanatide have all showed positive feedback.
Stock, those are some good questions. I'm interested if you ever got a response or acknowledgement of some of your questions/ points of emphasis, especially the one regarding IONSYS submitting. Not being familiar with that company, Is it comparing apples and apples? Were they successful in getting approved?
Horst sounded like a bumbling idiot. He has no business speaking to cameras and the press. Is there no one else on staff that can act as the speaker? Zerbe needs to take the approach when talking that less is more. The guy interviewing him had to cut him off several times because he was just rambling. He has a great opportunity to create investor interest and he blows it, imo.
I figured last night, but knowing the depth of the conversation, I'm sure it will take him a day or two to put it together. Hope not too long. :-)
Does that encourage us to do the same, especially since we have data to support the vastly improved lower incidents of tablets being discharged?
Actually the REAL news is that the company has completely wasted the last 8 months arguing about something and has gained zero ground while burning off another $90 million.
Let's be honest, the drug works and works very well. ACRX 04 will be approved as as a result of how it is administered. The only hang up we have here is jumping through more hoops to satisfy FDA requests. News of successful trials is really nothing as the issue is not how well the drug works.
C'mon, Adam. A stupid comment? Anybody who follows this company knows that the drug works very well. The drug will be a huge success if approved because of it's effectiveness and ease of use. It's not about the effectiveness, however, and that is why I am saying that today's news is not a surprise to anyone who is familiar with past results of Zalviso. I am uncomfortably deep and in the red here and have held solid for about 20 months now. Nobody wants this to go above $8 more than I, believe me.
It's amazing that you attack me for being a short for simply stating that today's pr was irrelevant for the stock price or success of Zalviso when you dominate the threads on this board as someone who just wants to pump the stock. I prefer to just discuss things as they are. I've never shorted a stock in my life and am heavily invested in here. I would advise that you check yourself, however, because as much as you despise those who short because of their constant bashing, you try to prevent only one side, also. Try to be an educator of the company instead of pumping all the time.